嗜酸性粒细胞过氧化物酶:一种不受鼻息肉状态影响的嗜酸性慢性鼻窦炎生物标志物
前瞻性纳入28例行鼻窦手术者,用自建免疫分析法测筛骨组织EPX及48重细胞因子-趋化因子阵列。EPX在CRSwNP对对照组、eCRS对neCRS、eCRSwNP及eCRSsNP对neCRSsNP均升高;EPX与组织嗜酸性粒细胞增多AUC为0.938,最佳切点470 ng/mL特异性100%、敏感性81.25%。结论:EPX与CRS组织嗜酸性粒细胞增多相关,不受息肉状态影响。
要点
- EPX在eCRS较neCRS升高(p=0.002),在eCRSwNP及eCRSsNP较neCRSsNP分别升高(p=0.023、p=0.015)。
- EPX诊断组织嗜酸性粒细胞增多AUC为0.938(95%CI 0.835-1.00),切点470 ng/mL特异性100%、敏感性81.25%。
- 仅EPX与SNOT-22(p=0.04)及Lund-Mackay评分(p=0.004)显著相关,IL-5未见。
核心结论
- EPX与CRS患者组织嗜酸性粒细胞增多相关,不受息肉状态影响。
- EPX与IL-5相关,可能可考虑作为抗IL-5治疗的生物标志物。
研究设计与样本
- 前瞻性纳入28例行鼻窦手术的受试者,分析筛骨组织的EPX免疫分析及48重细胞因子-趋化因子阵列。
- 临床严重度用SNOT-22和Lund-Mackay评分评估。
- 分组为对照组、息肉状态组(CRSwNP与CRSsNP)、组织嗜酸性粒细胞增多组(eCRS与neCRS)及其组合(eCRSwNP、eCRSsNP、neCRSsNP)。
- eCRS定义为每高倍视野嗜酸性粒细胞>10个。
- 无CRS或哮喘的受试者作为对照。
主要发现
- EPX在CRSwNP较对照升高(p=0.007),在eCRS较neCRS升高(p=0.002),在eCRSwNP及eCRSsNP较neCRSsNP分别升高(p=0.023、p=0.015)。
- eCRS较neCRS的IL-5升高(p=0.005)。
- eCRSwNP与eCRSsNP之间EPX或IL-5无显著差异。
- IL-5在eCRSwNP较neCRSsNP升高(p=0.019)。
- EPX与组织嗜酸性粒细胞增多的ROC曲线下面积为0.938(95%CI 0.835-1.00),最佳切点470 ng/mL对组织嗜酸性粒细胞增多的特异性为100%、敏感性为81.25%。
关键数值与推荐
- eCRS定义为每高倍视野嗜酸性粒细胞>10个。
- EPX诊断组织嗜酸性粒细胞增多的最佳切点为470 ng/mL,特异性100%、敏感性81.25%。
- 证据等级为3。
临床怎么用
- 作者认为EPX与CRS患者组织嗜酸性粒细胞增多相关,不受息肉状态影响。
- 作者认为EPX与IL-5相关,可能可考虑作为抗IL-5治疗的生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate eosinophil peroxidase (EPX) as a biomarker for tissue levels of eosinophilia, cytokines, and chemokines within chronic rhinosinusitis (CRS). METHODS: Twenty-eight subjects undergoing sinonasal surgery were prospectively enrolled. Ethmoid tissue was analyzed with an in-house EPX immunoassay and a 48-plex cytokine-chemokine array. Clinical severity was assessed using SNOT-22 and Lund-Mackay scores. Subjects were grouped as follows: controls, polyp status (CRS with [CRSwNP] and without nasal polyps [CRSsNP]), tissue eosinophilia (eosinophilic CRS [eCRS], non-eosinophilic CRS [neCRS]), or combinations thereof (eCRSwNP, eCRSsNP, neCRSsNP). eCRS was defined as >10 eosinophils per high power field (HPF). Subjects without CRS or asthma were enrolled as controls. RESULTS: EPX was elevated in CRSwNP compared to control (p = 0.007), in eCRS compared to neCRS (p = 0.002), and in eCRSwNP along with eCRSsNP compared to neCRSsNP (p = 0.023, p = 0.015, respectively). eCRS displayed elevated IL-5 compared to neCRS (p = 0.005). No significant differences in EPX or IL-5 were observed between eCRSwNP and eCRSsNP. IL-5 was elevated in eCRSwNP (p = 0.019) compared neCRSsNP. Area under the receiver operator characteristic curve was 0.938 (95% CI, 0.835-1.00) for EPX and tissue eosinophilia, with an optimal cut-point of 470 ng/mL being 100% specific and 81.25% sensitive for tissue eosinophilia. Linear regression revealed a strong correlation between EPX and IL-5 (R2 = 0.64, p < 0.001). Comparing EPX and IL-5, only EPX displayed significant correlation with SNOT-22 (p = 0.04) and Lund-Mackay score (p = 0.004). CONCLUSION: EPX is associated with tissue eosinophilia in CRS patients regardless of polyp status. EPX correlates with IL-5 and could be potentially considered a biomarker for anti-IL-5 therapies. LEVEL OF EVIDENCE: 3 Laryngoscope, 134:69-78, 2024.
引用
- Idler BM, Iijima K, Ochkur SI, et al. Eosinophil Peroxidase: A Biomarker for Eosinophilic Chronic Rhinosinusitis Agnostic of Polyp Status. Laryngoscope. 2023. PMID: 37255054. doi:10.1002/lary.30787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。